Dear Editor
We thank Dr Dawson et al. for their comments [Citation1]. The objective of our review was to focus particularly on the substantial published adult pneumococcal data that have been generated within the UK; these will be especially important for informed decision-making in the UK for the new higher valency adult pneumococcal conjugate vaccines that are expected to shortly become available. These local data include considerable data that specifically give valuable insight into the protection the 23-valent pneumococcal polysaccharide vaccine (PPV23) has afforded older UK adults against pneumococcal disease, and our conclusions were based on careful consideration of these [Citation2–5]. The data clearly show that PPV23 provides older UK adults with only limited short-term protection against invasive pneumococcal disease (IPD) [Citation2,Citation3] and has achieved no impact on IPD at the population level [Citation2] with various PPV23 serotypes now comprising an increasing proportion of IPD serotypes amongst older UK adults [Citation2,Citation5]. Local UK data are also unable to provide any compelling evidence to suggest that PPV23 provides older UK adults with meaningful protection against pneumococcal pneumonia [Citation4]. Our conclusions are consistent with those of the UK’s Joint Committee on Vaccination and Immunization (JCVI) [Citation6] and other leading internationally recognized pneumococcal experts from the UK [Citation7,Citation8]. This suggests that an alternative vaccine to PPV23 is needed to better protect older UK adults against pneumococcal disease with higher valency pneumococcal conjugate vaccines offering an attractive option. This reflects the clear body of evidence demonstrating the ability of pneumococcal conjugate vaccines to protect adults against pneumococcal disease [Citation9] and the subsequent wider industry effort to develop new higher valency pneumococcal conjugate vaccines specifically for use in adult populations.
Declaration of interest
A Vyse, J Campling, C Czudek, G Ellsbury, D Mendes, R-R Reinert are employees of Pfizer, which has an interest in pneumococcal vaccines. M Slack works as a contractor for Pfizer, which has an interest in pneumococcal vaccines. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Additional information
Funding
References
- Dawson R, Buchwald U, Johnson K, et al. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Exp Rev Vaccines. 2022;21(6): doi:https://doi.org/10.1080/14760584.2022.2047023
- Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent Polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50.
- Andrews N, Waight P, George R, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808. Epub 2012 Sep 18
- Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020 Oct;17(10):e1003326. PubMed PMID: 33095759; eng
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non- vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. PubMed PMID: 29395999; eng
- JCVI. Minute of the meeting on 07 October 2015.
- van Hoek AJ, Miller E. Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PloS One. 2016;11(2):e0149540. PubMed PMID: 26914907; PubMed Central PMCID: PMCPmc4767406. eng
- Goldblatt D, Miller E. Pneumococcal pneumonia. Thorax. 2020;75(1):6–7.
- Theilacker C, Fletcher M, Jodar L, et al. PCV13 vaccination of adults against pneumococcal disease: what we have learned from the community-acquired pneumonia immunization trial in adults (CAP-iTA). Microorganisms. 2022;10:127.